Redesigning the designer drug ecstasy:Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Simple item page
dc.contributor.authorGandy, Michael N
dc.contributor.authorMcIldowie, Matthew
dc.contributor.authorLewis, Katie
dc.contributor.authorWasik, Agata M
dc.contributor.authorSalomonczyk, Danielle
dc.contributor.authorWagg, Keith
dc.contributor.authorMillar, Zak A
dc.contributor.authorTindiglia, David
dc.contributor.authorHuot, Philippe
dc.contributor.authorJohnston, Tom
dc.contributor.authorThiele, Sherri
dc.contributor.authorBrotchie, Jonathan M
dc.date.accessioned2015-12-10T23:33:15Z
dc.date.issued2010
dc.date.updated2016-02-24T08:20:15Z
dc.description.abstractBurkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel α-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.
dc.identifier.issn2040-2503
dc.identifier.urihttp://hdl.handle.net/1885/69199
dc.publisherRoyal Society of Chemistry
dc.sourceMedChemComm
dc.subjectKeywords: 3,4 methylenedioxymethamphetamine; article; Burkitt lymphoma; cell viability; drug cytotoxicity; drug mechanism; drug potency; drug structure; drug synthesis; human; in vitro study; lymphoma cell line; priority journal
dc.titleRedesigning the designer drug ecstasy:Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity
dc.typeJournal article
local.bibliographicCitation.issue4
local.bibliographicCitation.lastpage293
local.bibliographicCitation.startpage287
local.contributor.affiliationGandy, Michael N, University of Western Australia
local.contributor.affiliationMcIldowie, Matthew, University of Western Australia
local.contributor.affiliationLewis, Katie, University of Western Australia
local.contributor.affiliationWasik, Agata M, University of Birmingham
local.contributor.affiliationSalomonczyk, Danielle, University of Toronto
local.contributor.affiliationWagg, Keith, College of Physical and Mathematical Sciences, ANU
local.contributor.affiliationMillar, Zak A, University of Western Australia
local.contributor.affiliationTindiglia, David, University of Western Australia
local.contributor.affiliationHuot, Philippe, Toronto Western Research Institute
local.contributor.affiliationJohnston, Tom, Toronto Western Research Institute
local.contributor.affiliationThiele, Sherri, Toronto Western Hospital
local.contributor.affiliationBrotchie, Jonathan M, Toronto Western Research Institute
local.contributor.authoremailrepository.admin@anu.edu.au
local.contributor.authoruidWagg, Keith, u3292392
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor030499 - Medicinal and Biomolecular Chemistry not elsewhere classified
local.identifier.ariespublicationf2965xPUB1953
local.identifier.citationvolume1
local.identifier.doi10.1039/c0md00108b
local.identifier.scopusID2-s2.0-79952527355
local.identifier.uidSubmittedByf2965
local.type.statusPublished Version

Downloads

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
01_Gandy_Redesigning_the_designer_drug_2010.pdf
Size:
172 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2024 LYRASIS